Table 4 Best response according to RECIST and treatment duration
Parameter | Non-continuous dosing (n = 11) | Continuous dosing (n = 28) | Total (n = 39) |
|---|---|---|---|
Status at study entry (SD/PD) | 1 (9%)/10 (91%) | 0 (0%)/28 (100%) | 1 (3%)/38 (97%) |
Best response | |||
- Stable disease | 6 (55%) | 16 (57%) | 22 (56%) |
- Progressive disease measurement proven | 4 (36%) | 9 (32%) | 13 (33%) |
- Progressive disease by clinical judgment | 1 (9%) | 3 (11%) | 4 (10%) |